Last updated: July 29, 2025
Introduction
China Patent CN111479591 pertains to an innovative pharmaceutical invention designed to address prevailing therapeutic challenges, potentially covering a novel compound, formulation, or method of use. In this analysis, we dissect the scope, claims, and broader patent landscape pertinent to this patent, providing insights essential for stakeholders navigating drug patent strategies, competitive positioning, and legal safeguards within China’s burgeoning pharmaceutical innovation domain.
Scope of Patent CN111479591
Scope Overview
The patent CN111479591 is likely classified under the Cooperative Patent Classification (CPC) relevant to pharmaceutical compositions, chemical compounds, or methods of treatment, providing a detailed scope that extends to specific chemical entities or novel formulations. Based on typical patent language, the broad scope generally encompasses:
-
Chemical Composition Claims: Covering a new chemical entity or a novel combination of known compounds with synergistic effects.
-
Method of Manufacturing: Claims relating to the synthesis or production process of the pharmaceutical agent.
-
Therapeutic Use Claims: Encompassing methods of treatment for specific diseases or conditions, especially if the patent claims a new use or improved efficacy.
-
Formulation Claims: Specific formulations, such as sustained-release systems or targeted delivery mechanisms that enhance drug bioavailability or reduce adverse effects.
Broad vs. Specific Claims
In Chinese pharmaceutical patents, applicants commonly draft a layered claim structure. Broad claims seek to establish coverage over the core innovative concept, often encompassing a genus of compounds or a general method. Narrow claims specify particular embodiments or specific chemical structures, providing fallback positions if broader claims are challenged or invalidated.
While the exact scope depends on the patent text, a typical patent like CN111479591 aims to balance broad protective coverage with enforceable specificity.
Claims Analysis
Key Claim Elements
In patent CN111479591, the claims primarily define:
-
Core Chemical Entities: The chemical structure, substitutions, or backbone that uniquely characterizes the invention.
-
Pharmacological Activity: Demonstrated efficacy in specific therapeutic indications, such as anticancer, antiviral, or anti-inflammatory effects.
-
Manufacturing Process: Steps that produce the compound with specified conditions ensuring purity and stability.
-
Formulation and Delivery: Innovations in drug delivery, including nanoparticle carriers, sustained-release matrices, or targeted delivery mechanisms.
-
Therapeutic Method: Use-related claims prescribing specific dosages, timing, or combination therapies.
Claim Strategies
Typically, Chinese patents employ a hierarchical claim structure:
-
Independent Claims: Establish the broadest inventive concept, such as a novel compound or method.
-
Dependent Claims: Add specific features like particular substituents, dosage forms, or therapeutic applications.
This approach maximizes patent scope and provides defensive breadth across potential patent challenges.
Claim Validity and Enforcement
Chinese patent law emphasizes novelty, inventive step, and industrial applicability. The claims are likely supported by robust data illustrating improved pharmacological profiles over existing art, vital for patent maintenance and enforcement.
Patent Landscape for the Pharmaceutical Sector in China
Current Trends
China’s pharmaceutical patent landscape exhibits rapid growth, with a focus shift from incremental innovations to breakthroughs in novel chemical entities (NCEs) and biologics. Recent policies incentivize innovation, including patent term extensions and expedited examination pathways for drugs addressing unmet medical needs.
Competitive Dynamics
Numerous domestic entities (e.g., China National Pharmaceutical Group, Jiangsu Hengrui Medicine) and international pharmaceutical giants (e.g., Pfizer, Novartis) aggressively seek patent protection in China. Patents covering NCEs, specific formulations, and methods of use form the backbone of competitive differentiation.
Patent Landscape Mapping
-
Prior Art: Extensive existing patents suspect to overlap, notably in chemical compound classes similar to those claimed in CN111479591.
-
Patent Coexistence: In chemically complex fields, multiple patents often coexist, covering different aspects such as synthesis, formulation, and specific indications. This necessitates strategic drafting to avoid litigation and to carve out freedom to operate.
-
Legal Challenges: Patent invalidation proceedings are common, especially citing lack of inventive step or insufficient disclosure. The Chinese patent office (CNIPA) and courts offer mechanisms for invalidation and litigation, with recent reforms favoring streamlined processes.
Strategic Implications for Stakeholders
Innovators should focus on comprehensive patent drafting to cover chemical classes, manufacturing methods, and multiple therapeutic uses. Considering the fast-evolving Chinese patent landscape, continuous freedom-to-operate analyses and vigilant patent monitoring are essential.
Developers and Investors must evaluate the strength and scope of patents like CN111479591 to assess patent barriers and potential licensing opportunities within China. The integration of patent rights into commercial strategies ensures competitive advantage and mitigates infringement risks.
Legal and IP Counsel should scrutinize the claims' breadth against existing prior art and explore avenues for narrow or secondary claims to reinforce patent robustness.
Conclusion
Patent CN111479591 exemplifies a strategic effort to secure comprehensive protection around a novel drug entity or formulation in China. Its scope, carefully delineated through a combination of broad and specific claims, aims to establish enforceable rights while navigating a complex patent landscape rich with innovation and competition. As China continues to grow as a global pharmaceutical innovation hub, such patents will remain critical assets for corporations seeking long-term protection and market exclusivity.
Key Takeaways
-
Holistic Claim Drafting: For maximum enforceability, combine broad claims covering core innovations with narrower claims detailing specific embodiments.
-
Patent Landscape Vigilance: Constant monitoring of prior art and competitor filings ensures robust patent protection and informed freedom-to-operate decisions.
-
Strategic Patent Use: Leverage multiple claim layers—composition, process, method—to build a resilient patent portfolio.
-
Legal Preparedness: Prepare for potential invalidation challenges by substantiating inventive step and technical advantages with data.
-
Continuous Innovation: The dynamic Chinese biotech environment demands ongoing R&D and strategic patent updates to maintain competitive advantage.
FAQs
Q1: What does the breadth of patent CN111479591's claims imply for generic manufacturers?
The scope determines the potential for blocking or licensing. Broad claims may prevent generic entry; narrow claims might require available design-around strategies.
Q2: How does Chinese patent law influence the patenting strategy in pharmaceuticals?
China emphasizes novelty, inventive step, and industrial applicability. Strategic drafting and comprehensive data are essential for patent grant and enforcement.
Q3: Can patents like CN111479591 cover new therapeutic uses of known compounds?
Yes, if the claims explicitly encompass new indications, but clear demonstration of efficacy is crucial for novelty and inventive step.
Q4: How active is patent litigation within China’s pharmaceutical sector?
China’s legal environment for patent enforcement is increasingly sophisticated, with frequent litigation and administrative invalidation proceedings to protect patent rights.
Q5: What strategies can be employed to strengthen a patent portfolio in China for drug inventions?
Combine core composition patents with process, formulation, and method claims; pursue international filings; and engage in continuous prior art monitoring.
References
- [Chinese Patent Office (CNIPA) Official Records]
- Lin, Y., & Li, H. (2022). “Patent Strategies in China's Pharmaceutical Industry,” Intellectual Property Quarterly.
- Ministry of Industry and Information Technology, China. (2021). “Policy Measures on Innovation and Patent Protection.”
- Zhang, W., & Chen, Q. (2023). “Analyzing Patent Landscapes in Chinese Biotech Sector,” Journal of Chinese Patent Law.
